SWTX Quote, Financials, Valuation and Earnings

ADMA Biologics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of 95.19%. SpringWorks Therapeutics's return on equity of -46.69% beat ADMA Biologics's return on equity of 93.41%.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 35.36%. Given that SpringWorks Therapeutics has higher upside potential than ADMA Biologics, analysts believe SpringWorks Therapeutics is more attractive than ADMA Biologics.

SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. SpringWorks Therapeutics's net income of -$77.3M is lower than ADMA Biologics's net income of $111.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 22.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus 10.61x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Atara Biotherapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -38.75%. SpringWorks Therapeutics's return on equity of -46.69% beat Atara Biotherapeutics's return on equity of -2818.48%.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand Atara Biotherapeutics has an analysts' consensus of $12.25 which suggests that it could grow by 70.85%. Given that Atara Biotherapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Atara Biotherapeutics is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison Atara Biotherapeutics has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.322%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atara Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Atara Biotherapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are larger than Atara Biotherapeutics quarterly revenues of $32.8M. SpringWorks Therapeutics's net income of -$77.3M is lower than Atara Biotherapeutics's net income of -$12.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Atara Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus 0.42x for Atara Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Grace Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -46.69% beat Grace Therapeutics's return on equity of --.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand Grace Therapeutics has an analysts' consensus of $11.88 which suggests that it could grow by 444.87%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison Grace Therapeutics has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.308%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grace Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Grace Therapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are larger than Grace Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$77.3M is lower than Grace Therapeutics's net income of -$4.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Grace Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus -- for Grace Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -225.53%. SpringWorks Therapeutics's return on equity of -46.69% beat Insmed's return on equity of -41989.34%.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand Insmed has an analysts' consensus of $95.66 which suggests that it could grow by 25%. Given that SpringWorks Therapeutics has higher upside potential than Insmed, analysts believe SpringWorks Therapeutics is more attractive than Insmed.

SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Insmed quarterly revenues of $104.4M. SpringWorks Therapeutics's net income of -$77.3M is higher than Insmed's net income of -$235.5M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus 34.51x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.